---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-004258"
form_type: "8-K"
ticker: "ACTU"
cik: "0001652935"
company_name: "ACTUATE THERAPEUTICS, INC."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T22:07:41.860682+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Actuate Therapeutics presents Phase 2 elraglusib data showing overall survival benefit in pancreatic cancer

## Summary
- Phase 2 (Actuate-1801 Part 3B) data of elraglusib with gemcitabine/nab-paclitaxel showed overall survival benefit in first-line metastatic pancreatic cancer.
- KOL event featured four GI oncology experts who discussed elraglusib's mechanism targeting EMT, NF-kB, and immune activation.
- Dr. Colin Weekes stated elraglusib is the first drug in years to improve outcomes on standard chemotherapy backbones.
- Drug was well-tolerated; neutropenia occurred but no febrile neutropenia; transient vision changes resolved within 24 hours.
- Study PI Dr. Deva Mahalingam highlighted unique GSK-3 beta inhibition and survival curve separation in a challenging patient population.

## SEC filing metadata
- accession: 0001683168-25-004258
- form_type: 8-K
- ticker: ACTU
- cik: 0001652935
- company_name: ACTUATE THERAPEUTICS, INC.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652935/000168316825004258/0001683168-25-004258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652935/000168316825004258/actuate_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-004258
- JSON: https://secwatch.observer/filing/0001683168-25-004258.json
- Plain text: https://secwatch.observer/filing/0001683168-25-004258.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.